The Final Chapter for Novan: Shares Cease Trading as Liquidation Concludes

Investors holding shares of Novan have reached the end of the line. The company’s stock is now effectively worthless, a direct result of its 2023 bankruptcy proceedings and the subsequent sale of its core business operations. Recent trading data from early February confirms a complete absence of volume, indicating the delisting process is final.

A Bankruptcy with No Recovery for Shareholders

The decisive event occurred in July 2023 when Novan filed for Chapter 11 creditor protection. As part of that process, the company sold substantially all of its assets to Ligand Pharmaceuticals. This move stripped the publicly traded entity of any fundamental business foundation, transferring its entire operational capacity to the buyer.

Should investors sell immediately? Or is it worth buying Novan?

For remaining equity holders, the implications are stark. The established hierarchy in such bankruptcy cases is clear: secured creditors and other claimants are prioritized for any remaining value. Common shareholders typically stand last in line and receive nothing, a scenario strongly supported by the recent trading halt and the apparent total loss for investors.

Key Points for Former Investors

• Operational Wind-Down: The company’s business activities were either terminated or fully transferred during 2023.
• Ticker Inactivity: The listing under the symbol NOVN now shows zero trading activity.
• Bankruptcy Status: The insolvency proceedings are in their final phase.

The company’s former research pipeline, including the development of berdazimer gel for molluscum contagiosum, continues under the stewardship of Ligand Pharmaceuticals. However, this provides no residual value to the original Novan corporate shell. The liquidation of this remaining entity is proceeding and will conclude without any distribution to its former shareholders, cementing the total loss for those who held the stock.